Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).
1 finding from 1 review
Death (any cause) · patients with diarrhoea due to Shiga toxin‐producing E. coli
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
It is very uncertain whether long (> 20 cm) changes death from any cause at day 28 of compared with short (≤ 20 cm) catheter (very low certainty).
1 finding from 1 review
Death from any cause · AKI patients receiving CKRT
It is very uncertain whether CVVHD changes death from any cause compared with CVVH or CVVHDF (very low certainty).
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
It is very uncertain whether surface‐modified changes death from any cause at day 28 of compared with standard double‐lumen catheter with identical geometry and flow design (very low certainty).
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death from any cause at day 28 of · AKI patients receiving CKRT
It is very uncertain whether CVVHDF changes death from any cause at day 28 of compared with CVVH (very low certainty).
1 finding from 1 review
Relapse · adults with renal vasculitis
Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).
1 finding from 1 review
Death (any cause) · heart failure with chronic kidney disease
ACUTE: Serelaxin showed no clear difference in death (any cause) compared with placebo (low certainty).
1 finding from 1 review
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: ACEi or ARB showed no clear difference in death (any cause) ( compared with placebo (low certainty).
1 finding from 1 review
Hospitalisation (any cause) · heart failure with chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) ( · heart failure with chronic kidney disease
CHRONIC: Beta‐blockers probably leads to lower death (any cause) ( compared with placebo (moderate certainty).
1 finding from 1 review